CLINICAL_TRIALS
trial_result
· 2025-09-08
Clinical Trial Update: A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype [Phase 2]
Summary
A Phase 2 study of VX-864 in Alpha-1 Antitrypsin Deficiency (PiZZ genotype) was terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Alpha-1 Antitrypsin Deficiency | Phase 2 | Status: TERMINATED | Results posted: 2025-09-08